Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMUS: ESK-001 in Systemic Lupus Erythematosus
NCT05966480Phase 2Active, not recruiting
- Sponsor
- Alumis Inc.
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of envudeucitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Alumis Inc. Primary endpoint: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at 48 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
envudeucitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05966480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966480.